ArticleHaematologica2023

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.

Xiang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.